EE200300373A - Meetod kamptotetsiini analoogide sünteesimiseks kasutatavate ühendite valmistamiseks ning kamptotetsiini analoogide terviksüntees - Google Patents

Meetod kamptotetsiini analoogide sünteesimiseks kasutatavate ühendite valmistamiseks ning kamptotetsiini analoogide terviksüntees

Info

Publication number
EE200300373A
EE200300373A EEP200300373A EEP200300373A EE200300373A EE 200300373 A EE200300373 A EE 200300373A EE P200300373 A EEP200300373 A EE P200300373A EE P200300373 A EEP200300373 A EE P200300373A EE 200300373 A EE200300373 A EE 200300373A
Authority
EE
Estonia
Prior art keywords
synthesis
camptothecin analogs
preparation
compounds used
integral
Prior art date
Application number
EEP200300373A
Other languages
English (en)
Inventor
Ogawa Takanori
Nishiyama Hiroyuki
Uchida Miyuki
Sawada Seigo
Original Assignee
Kabushiki Kaisha Yakult Honsha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabushiki Kaisha Yakult Honsha filed Critical Kabushiki Kaisha Yakult Honsha
Publication of EE200300373A publication Critical patent/EE200300373A/et
Publication of EE05361B1 publication Critical patent/EE05361B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C221/00—Preparation of compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/13—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups
    • C07C205/20—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups and hydroxy groups bound to carbon atoms of six-membered aromatic rings
    • C07C205/21—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups and hydroxy groups bound to carbon atoms of six-membered aromatic rings having nitro groups and hydroxy groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C205/22—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups and hydroxy groups bound to carbon atoms of six-membered aromatic rings having nitro groups and hydroxy groups bound to carbon atoms of the same non-condensed six-membered aromatic ring having one nitro groups bound to the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
    • C07C205/35—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C205/36—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
    • C07C205/37—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/44—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/45—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/22—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EEP200300373A 2001-02-21 2002-02-21 Meetod kamptotetsiini analoogide snteesimiseks kasutatavate hendite valmistamiseks ning kamptotetsiini analoogide terviksntees EE05361B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001045430 2001-02-21
JP2001309322 2001-10-05
PCT/JP2002/001538 WO2002066416A1 (en) 2001-02-21 2002-02-21 Method of synthesizing camptothecin-relating compounds

Publications (2)

Publication Number Publication Date
EE200300373A true EE200300373A (et) 2003-10-15
EE05361B1 EE05361B1 (et) 2010-12-15

Family

ID=26609837

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300373A EE05361B1 (et) 2001-02-21 2002-02-21 Meetod kamptotetsiini analoogide snteesimiseks kasutatavate hendite valmistamiseks ning kamptotetsiini analoogide terviksntees

Country Status (23)

Country Link
US (2) US7126000B2 (et)
EP (1) EP1378505B1 (et)
JP (2) JP4210119B2 (et)
KR (2) KR100858972B1 (et)
CN (1) CN100408550C (et)
AR (2) AR035684A1 (et)
AU (1) AU2002237527B2 (et)
BG (2) BG108031A (et)
BR (1) BR0207470A (et)
CA (2) CA2683768C (et)
CZ (1) CZ20032470A3 (et)
EE (1) EE05361B1 (et)
HU (1) HUP0302755A3 (et)
IL (2) IL156949A0 (et)
MX (1) MXPA03007528A (et)
NO (2) NO328628B1 (et)
NZ (2) NZ527615A (et)
PL (2) PL217238B1 (et)
RO (2) RO125158A2 (et)
RU (1) RU2308447C2 (et)
SK (2) SK288149B6 (et)
TW (1) TWI245768B (et)
WO (1) WO2002066416A1 (et)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ299329B6 (cs) * 2003-08-26 2008-06-18 Pliva-Lachema A.S. Zpusob výroby 7-ethyl-10-[ 4-(1-piperidino)-1-piperidino]karbonyloxykamptothecinu
CZ299593B6 (cs) * 2003-12-16 2008-09-10 Pliva-Lachema A. S. Zpusob výroby 7-ethyl-10-hydroxykamptothecinu
WO2006016203A1 (en) * 2004-08-09 2006-02-16 Shilpa Medicare Limited An improved process for the preparation of irinotecan hydrochloride trihydrate
ES2391775T3 (es) * 2004-11-05 2012-11-29 Samyang Biopharmaceuticals Corporation Formulación farmacéutica para aumentar la solubilidad de compuestos de 10-hidroxicamptotecina en disolventes polares no acuosos
PL1846412T3 (pl) * 2005-02-07 2010-03-31 Fermion Oy Sposób wytwarzania 7-etylo-10-hydroksykamptotecyny
PL1928883T3 (pl) * 2005-02-08 2014-03-31 Fermion Oy Sposób otrzymywania chlorowodorku irynotekanu
US7662964B2 (en) 2005-02-08 2010-02-16 Fermion Oy Process for producing [1,4′] bipiperidinyl-1′-carbonyl chloride or hydrochloride thereof
US8112154B2 (en) * 2005-04-13 2012-02-07 The Cleveland Clinic Foundation Systems and methods for neuromodulation using pre-recorded waveforms
TWI375678B (en) * 2005-06-09 2012-11-01 Yakult Honsha Kk A method of preparation of a tricyclic ketone
EP1910269B1 (en) * 2005-08-03 2013-09-18 Avra Laboratories PVT. Ltd. Method of synthesizing key intermediates for the production of camptothecin derivatives
EP1803725A1 (en) * 2005-12-13 2007-07-04 W.C. Heraeus GmbH Methods for preparing irinotecan
US9220889B2 (en) 2008-02-11 2015-12-29 Intelect Medical, Inc. Directional electrode devices with locating features
CN101824038B (zh) * 2009-03-06 2013-08-21 复旦大学 喜树碱及其类似物的制备方法
JP5734295B2 (ja) 2009-08-27 2015-06-17 ザ クリーブランド クリニック ファウンデーション 組織活性の部位を推定するためのシステムおよび方法
JP5599094B2 (ja) * 2010-05-20 2014-10-01 国立大学法人 千葉大学 ニトリル化合物の製造方法
CA2802708A1 (en) 2010-06-14 2011-12-22 Boston Scientific Neuromodulation Corporation Programming interface for spinal cord neuromodulation
US9925382B2 (en) 2011-08-09 2018-03-27 Boston Scientific Neuromodulation Corporation Systems and methods for stimulation-related volume analysis, creation, and sharing
AU2013308906B2 (en) 2012-08-28 2016-07-21 Boston Scientific Neuromodulation Corporation Point-and-click programming for deep brain stimulation using real-time monopolar review trendlines
WO2014070290A2 (en) 2012-11-01 2014-05-08 Boston Scientific Neuromodulation Corporation Systems and methods for voa model generation and use
US8722886B1 (en) * 2012-11-13 2014-05-13 Bionumerik Pharmaceuticals, Inc. Methods for the total chemical synthesis of enantiomerically-pure 7-(2′-trimethylsilyl)ethyl camptothecin
US9959388B2 (en) 2014-07-24 2018-05-01 Boston Scientific Neuromodulation Corporation Systems, devices, and methods for providing electrical stimulation therapy feedback
US10272247B2 (en) 2014-07-30 2019-04-30 Boston Scientific Neuromodulation Corporation Systems and methods for stimulation-related volume analysis, creation, and sharing with integrated surgical planning and stimulation programming
US10265528B2 (en) 2014-07-30 2019-04-23 Boston Scientific Neuromodulation Corporation Systems and methods for electrical stimulation-related patient population volume analysis and use
US9974959B2 (en) 2014-10-07 2018-05-22 Boston Scientific Neuromodulation Corporation Systems, devices, and methods for electrical stimulation using feedback to adjust stimulation parameters
EP3209666B1 (en) * 2014-10-22 2019-08-21 Vivacitas Oncology Inc. Methods and systems for camptothecin analog synthesis
US10780283B2 (en) 2015-05-26 2020-09-22 Boston Scientific Neuromodulation Corporation Systems and methods for analyzing electrical stimulation and selecting or manipulating volumes of activation
US9956419B2 (en) 2015-05-26 2018-05-01 Boston Scientific Neuromodulation Corporation Systems and methods for analyzing electrical stimulation and selecting or manipulating volumes of activation
US10441800B2 (en) 2015-06-29 2019-10-15 Boston Scientific Neuromodulation Corporation Systems and methods for selecting stimulation parameters by targeting and steering
WO2017003946A1 (en) 2015-06-29 2017-01-05 Boston Scientific Neuromodulation Corporation Systems and methods for selecting stimulation parameters based on stimulation target region, effects, or side effects
WO2017062378A1 (en) 2015-10-09 2017-04-13 Boston Scientific Neuromodulation Corporation System and methods for clinical effects mapping for directional stimulations leads
US10716942B2 (en) 2016-04-25 2020-07-21 Boston Scientific Neuromodulation Corporation System and methods for directional steering of electrical stimulation
CN109416937A (zh) 2016-06-24 2019-03-01 波士顿科学神经调制公司 用于临床效果的视觉分析的系统和方法
US10350404B2 (en) 2016-09-02 2019-07-16 Boston Scientific Neuromodulation Corporation Systems and methods for visualizing and directing stimulation of neural elements
US10780282B2 (en) 2016-09-20 2020-09-22 Boston Scientific Neuromodulation Corporation Systems and methods for steering electrical stimulation of patient tissue and determining stimulation parameters
AU2017341910B2 (en) 2016-10-14 2020-05-14 Boston Scientific Neuromodulation Corporation Systems and methods for closed-loop determination of stimulation parameter settings for an electrical simulation system
AU2017391436B2 (en) 2017-01-03 2020-06-18 Boston Scientific Neuromodulation Corporation Systems and methods for selecting MRI-compatible stimulation parameters
US10589104B2 (en) 2017-01-10 2020-03-17 Boston Scientific Neuromodulation Corporation Systems and methods for creating stimulation programs based on user-defined areas or volumes
US10625082B2 (en) 2017-03-15 2020-04-21 Boston Scientific Neuromodulation Corporation Visualization of deep brain stimulation efficacy
WO2018187090A1 (en) 2017-04-03 2018-10-11 Boston Scientific Neuromodulation Corporation Systems and methods for estimating a volume of activation using a compressed database of threshold values
EP3651849B1 (en) 2017-07-14 2023-05-31 Boston Scientific Neuromodulation Corporation Estimating clinical effects of electrical stimulation
EP3634569A1 (en) 2017-08-15 2020-04-15 Boston Scientific Neuromodulation Corporation Systems and methods for controlling electrical stimulation using multiple stimulation fields
EP3784331B1 (en) 2018-04-27 2023-01-18 Boston Scientific Neuromodulation Corporation Multi-mode electrical stimulation systems and methods of making and using
WO2019210214A1 (en) 2018-04-27 2019-10-31 Boston Scientific Neuromodulation Corporation Systems for visualizing and programming electrical stimulation
US11434196B2 (en) * 2019-01-15 2022-09-06 Laurus Labs Limited Process for preparation of 2-Amino-5-hydroxy propiophenone

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391745A (en) * 1992-07-23 1995-02-21 Sloan-Kettering Institute For Cancer Research Methods of preparation of camptothecin analogs
JPH07101956A (ja) * 1993-10-05 1995-04-18 Tanabe Seiyaku Co Ltd ヒドロキシカンプトテシン化合物の製法
KR960029336A (ko) * 1995-01-09 1996-08-17 김충환 캄토테신 유도체, 그의 제조 방법 및 이를 함유하는 항암제
JPH08225482A (ja) * 1995-02-22 1996-09-03 Dai Ichi Seiyaku Co Ltd テトラロン関連化合物及びその製法
TW438775B (en) 1995-04-07 2001-06-07 Pharmacia & Upjohn Co Llc Novel intermediates and process for the manufacture of camptothecin derivatives (CPT-11) and related compounds
CZ133898A3 (cs) 1995-11-02 1998-08-12 Glaxo Wellcome Inc. Způsob výroby derivátů camptothecinu
SG104284A1 (en) * 1996-10-30 2004-06-21 Tanabe Seiyaku Co S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof

Also Published As

Publication number Publication date
PL399009A1 (pl) 2012-09-10
SK288073B6 (sk) 2013-05-03
AU2002237527B2 (en) 2007-01-04
JPWO2002066416A1 (ja) 2004-09-24
MXPA03007528A (es) 2003-12-11
EP1378505B1 (en) 2014-11-05
KR100858972B1 (ko) 2008-09-17
RU2003128530A (ru) 2005-03-27
NO20093402L (no) 2003-10-10
EP1378505A1 (en) 2004-01-07
KR20030077631A (ko) 2003-10-01
KR20080012383A (ko) 2008-02-11
US7126000B2 (en) 2006-10-24
EE05361B1 (et) 2010-12-15
HUP0302755A3 (en) 2008-03-28
IL156949A0 (en) 2004-02-08
JP4210119B2 (ja) 2009-01-14
HUP0302755A2 (hu) 2003-12-29
WO2002066416A1 (en) 2002-08-29
EP1378505A4 (en) 2006-09-27
AR082663A2 (es) 2012-12-26
NO20033579L (no) 2003-10-10
SK288149B6 (sk) 2013-12-02
RO122639B1 (ro) 2009-10-30
NZ527615A (en) 2004-12-24
CA2683768A1 (en) 2002-08-29
US20070010674A1 (en) 2007-01-11
BG111453A (en) 2013-09-30
RO125158A2 (ro) 2010-01-29
US7378555B2 (en) 2008-05-27
BG108031A (bg) 2005-04-30
CA2683768C (en) 2013-05-28
PL363440A1 (en) 2004-11-15
JP2008273952A (ja) 2008-11-13
SK11472003A3 (sk) 2004-03-02
CN1492851A (zh) 2004-04-28
RO122639B9 (ro) 2014-03-28
NO20033579D0 (no) 2003-08-13
US20040106830A1 (en) 2004-06-03
CZ20032470A3 (cs) 2004-02-18
PL218065B1 (pl) 2014-10-31
PL217238B1 (pl) 2014-06-30
TWI245768B (en) 2005-12-21
AR035684A1 (es) 2004-06-23
IL156949A (en) 2009-09-01
NO328628B1 (no) 2010-04-12
CN100408550C (zh) 2008-08-06
JP4805967B2 (ja) 2011-11-02
CA2437702A1 (en) 2002-08-29
BR0207470A (pt) 2008-04-08
KR100864692B1 (ko) 2008-10-23
NO331656B1 (no) 2012-02-13
NZ534374A (en) 2004-12-24
RU2308447C2 (ru) 2007-10-20
CA2437702C (en) 2010-04-06

Similar Documents

Publication Publication Date Title
EE200300373A (et) Meetod kamptotetsiini analoogide sünteesimiseks kasutatavate ühendite valmistamiseks ning kamptotetsiini analoogide terviksüntees
CY2007029I2 (el) Μεθοδος για την παρασκευη υποκατεστημενων οκτανοϋλ-αμιδιων
NO20054715L (no) Fremgangsmater og mellomprodukter for fremstilling av anti-cancer forbindelser
NO20035162D0 (no) Fremgangsmåte for fremstilling av prostaglandiner og analoger derav
EE200300329A (et) Meetod peroraalselt manustatavate epotiloonide biosaadavuse suurendamiseks ning selles kasutatav komplekt, ravimkoostis ja farmatseutiline ravimvorm
NO20042680L (no) Fremgangsmater for fremstilling av O-demetylvenflaxine
DE60217126D1 (de) Herstellung von aminopyrimidinverbindungen
IL158831A0 (en) METHODS OF ADMINISTERING ANTI-TNFalpha ANTIBODIES
FI20000564A (fi) Menetelmä nanolaminaattien valmistamiseksi
DE60216507D1 (de) Verfahren zur herstellung von polyetherimiden
FI20011889A (fi) Menetelmä ksylitolin valmistamiseksi
EE05308B1 (et) Sulfoonamiid-asendatud imidasotriasinoonide valmistamismeetod
EE05247B1 (et) Meetod imidasoolhendite valmistamiseks
IL153316A0 (en) Isotopically labeled analogs of taxane and methods for the production thereof
DE60233589D1 (de) Verfahren zur herstellung von echinocandinderivaten
EE05403B1 (et) Tehniline snteesimeetod tropenooli valmistamiseks
HUP0303055A3 (en) Polymorphs of zaleplon and methods for the preparation thereof and pharmaceutical compositions containing them
DE60033207D1 (de) Werkzeug zur herstellung von nockenwellen durch einwalzen
NO20035586D0 (no) Fremgangsmåte for fremstilling av cykloheksanol-derivater
ITMI20011132A1 (it) Procedimento per la preparazione dell'acido 1-amminometil-1-cicloesanacetico
DE60205521D1 (de) Verfahren zur Herstellung linearer Organohydrosiloxanen
EE200200410A (et) Meetod atsetüülamidiniofenüülalanüültsükloheksüülglütsüülpüridinioalaniinamiidide valmistamiseks ning selleks vajalikud lähte- ja vaheühendid
DE60227896D1 (de) Verfahen zur Herstellung von Polyalkylphenoxyaminoalkanen
NO20033356L (no) Fremgangsmåte for fremstilling av DTPA-monoamider
HK1054551B (zh) 製備(3-氯-4-氟苯基)-胺化合物的方法

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20150221